Monday, 20 February 2012
Autoimmune Blistering Skin Disease
MBL have launched a new CE marked ELISA Kit: An anti-type VII collagen ELISA for the diagnosis and monitoring of disease activity in patients with epidermolysis bullosa acquisita (EBA).
EBA is an autoimmune blistering skin disease characterized by the presence of IgG against Type VII Collagen. Type VII Collagen consists of a central collagenous domain flanked by an amino terminal non collagenous domain (NC1) and a carboxy terminal non collagenous domain (NC2). Major epitopes for anti-typeVII collagen autoantibodies reside in NC1 and minor epitopes in NC2 (Mei Chen et al, J.Biol. Chem. 276, p21649, 2001)
The anti-type VII collagen ELISA available from MBL recognises epitopes for autoantibodies in both the NC1 and NC2 domains and can specifically diagnose EBA patients with anti-type VII collagen autoantibodies. In addition, Kurei et al*, have shown that this ELISA reacts only with EBA sera and not with sera from bullous pemphigoid patients.
EBA and bullous pemphigoid are similar in terms of clinical symptoms, but the diseases are sometimes different in therapy, EBA cases often require high doses of systemic corticosteroids and a wide variety of immunosuppressants. Therefore it is important to distinguish EBA from bullous pemphigoid. The NC1 and NC2 ELISA from MBL is more clinically relevant than the NC1 ELISA currently employed in many clinics and is useful in the diagnosis of EBA patients.
*Please click here to see the publication by Kurei et al, demonstrating the reactivity of the anti-type VII collagen ELISA with sera from EBA and bullous pemphigoid patients.
Product Code: RG-7845E
Anti-TypeVII collagen ELISA Kit (CE Mark)